PCI Biotech Holding ASA (PCIB.OL)
NOK 1.33
(-0.38%)
NOK 1.33
(-0.38%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 25.23 Million NOK | -55.3% |
| 2022 | 56.44 Million NOK | -34.39% |
| 2021 | 86.02 Million NOK | 4.76% |
| 2020 | 82.12 Million NOK | -7.53% |
| 2019 | 88.8 Million NOK | 99.47% |
| 2018 | 44.51 Million NOK | 2.51% |
| 2017 | 43.43 Million NOK | 31.5% |
| 2016 | 33.02 Million NOK | 1.22% |
| 2015 | 32.62 Million NOK | -10.58% |
| 2014 | 36.49 Million NOK | 24.43% |
| 2013 | 29.32 Million NOK | 7.2% |
| 2012 | 27.35 Million NOK | 11.66% |
| 2011 | 24.49 Million NOK | -8.2% |
| 2010 | 26.68 Million NOK | 1.48% |
| 2009 | 26.29 Million NOK | 34.83% |
| 2008 | 19.5 Million NOK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 5.84 Million NOK | -3.5% |
| 2024 Q2 | 5.84 Million NOK | 0.0% |
| 2023 Q2 | 6.32 Million NOK | -0.85% |
| 2023 FY | 24.86 Million NOK | -55.96% |
| 2023 Q4 | 6.05 Million NOK | 0.0% |
| 2023 Q3 | 6.05 Million NOK | -4.28% |
| 2023 Q1 | 6.37 Million NOK | -9.65% |
| 2022 Q4 | 7.06 Million NOK | -35.5% |
| 2022 FY | 56.44 Million NOK | -34.39% |
| 2022 Q1 | 22.8 Million NOK | -2.02% |
| 2022 Q2 | 15.64 Million NOK | -31.41% |
| 2022 Q3 | 10.94 Million NOK | -30.02% |
| 2021 Q4 | 23.27 Million NOK | 3.41% |
| 2021 Q2 | 19.08 Million NOK | -9.86% |
| 2021 Q1 | 21.17 Million NOK | -0.88% |
| 2021 FY | 86.02 Million NOK | 4.76% |
| 2021 Q3 | 22.5 Million NOK | 17.93% |
| 2020 Q2 | 22.25 Million NOK | 39.3% |
| 2020 Q3 | 22.53 Million NOK | 1.28% |
| 2020 Q4 | 21.36 Million NOK | -5.21% |
| 2020 FY | 82.12 Million NOK | -7.53% |
| 2020 Q1 | 15.97 Million NOK | -36.93% |
| 2019 FY | 88.8 Million NOK | 99.47% |
| 2019 Q2 | 27.05 Million NOK | 50.87% |
| 2019 Q4 | 25.32 Million NOK | 36.95% |
| 2019 Q3 | 18.49 Million NOK | -31.63% |
| 2019 Q1 | 17.92 Million NOK | 25.57% |
| 2018 FY | 44.51 Million NOK | 2.51% |
| 2018 Q4 | 14.27 Million NOK | 70.26% |
| 2018 Q3 | 8.38 Million NOK | 16.59% |
| 2018 Q2 | 7.19 Million NOK | -50.94% |
| 2018 Q1 | 14.66 Million NOK | -7.93% |
| 2017 Q4 | 15.92 Million NOK | 52.3% |
| 2017 FY | 43.43 Million NOK | 31.5% |
| 2017 Q1 | 9.85 Million NOK | 42.74% |
| 2017 Q2 | 7.2 Million NOK | -26.86% |
| 2017 Q3 | 10.45 Million NOK | 45.1% |
| 2016 Q1 | 7.3 Million NOK | -14.4% |
| 2016 FY | 33.02 Million NOK | 1.22% |
| 2016 Q4 | 6.9 Million NOK | -27.6% |
| 2016 Q3 | 9.53 Million NOK | 2.73% |
| 2016 Q2 | 9.28 Million NOK | 26.98% |
| 2015 Q3 | 9.41 Million NOK | 35.21% |
| 2015 FY | 32.62 Million NOK | -10.58% |
| 2015 Q1 | 7.71 Million NOK | -25.02% |
| 2015 Q2 | 6.96 Million NOK | -9.68% |
| 2015 Q4 | 8.53 Million NOK | -9.31% |
| 2014 Q1 | 9.4 Million NOK | 0.44% |
| 2014 Q2 | 8.38 Million NOK | -10.9% |
| 2014 Q3 | 8.41 Million NOK | 0.39% |
| 2014 Q4 | 10.28 Million NOK | 22.18% |
| 2014 FY | 36.49 Million NOK | 24.43% |
| 2013 Q1 | 7.24 Million NOK | -17.71% |
| 2013 Q2 | 5.89 Million NOK | -18.69% |
| 2013 Q3 | 6.9 Million NOK | 17.27% |
| 2013 Q4 | 9.36 Million NOK | 35.63% |
| 2013 FY | 29.32 Million NOK | 7.2% |
| 2012 Q1 | 6.2 Million NOK | -49.59% |
| 2012 Q4 | 8.8 Million NOK | 9.12% |
| 2012 Q3 | 8.06 Million NOK | 88.0% |
| 2012 Q2 | 4.29 Million NOK | -30.88% |
| 2012 FY | 27.35 Million NOK | 11.66% |
| 2011 Q1 | 4.03 Million NOK | -40.88% |
| 2011 FY | 24.49 Million NOK | -8.2% |
| 2011 Q2 | 5.12 Million NOK | 26.96% |
| 2011 Q3 | 3.01 Million NOK | -41.13% |
| 2011 Q4 | 12.31 Million NOK | 307.92% |
| 2010 Q3 | 4.52 Million NOK | -29.26% |
| 2010 Q1 | 5.71 Million NOK | -10.87% |
| 2010 FY | 26.68 Million NOK | 1.48% |
| 2010 Q2 | 6.39 Million NOK | 11.83% |
| 2010 Q4 | 6.83 Million NOK | 51.08% |
| 2009 Q4 | 6.41 Million NOK | -6.79% |
| 2009 Q3 | 6.88 Million NOK | 59.26% |
| 2009 Q2 | 4.32 Million NOK | 0.0% |
| 2009 FY | 26.29 Million NOK | 34.83% |
| 2008 FY | 19.5 Million NOK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Arctic Bioscience AS | -5730.00 NOK | 440431.588% |
| Aqua Bio Technology ASA | 18.46 Million NOK | -36.642% |
| ArcticZymes Technologies ASA | 97.26 Million NOK | 74.06% |
| BerGenBio ASA | 192.17 Million NOK | 86.871% |
| Hofseth BioCare ASA | 156.04 Million NOK | 83.831% |
| Thor Medical ASA | 7.16 Million NOK | -252.339% |
| Ultimovacs ASA | 215.73 Million NOK | 88.305% |